Abstract | BACKGROUND: METHODS: RESULTS: Sixty-two patients were enrolled. Thirty-two of 62 patients had stage IIIC disease, and 26 of 62 patients had stage IV disease. According to an intent-to-treat analysis, 55 patients (89%) experienced a clinical complete remission. At a median potential follow-up of 11.4 years, the median progression-free survival was 18.9 months, and the median survival was 5.4 years. The most serious toxicity was grade 3/4 neutropenic fever (35%). Although all participants developed peripheral neuropathy, improvement in neuropathic symptoms began with the decrease or cessation of paclitaxel. CONCLUSIONS: The studied regimen yielded a high response rate and encouraging overall survival. The current data and those reported by the Japanese Gynecologic Oncology Group suggest that further study is warranted of dose-dense or dose-intense paclitaxel regimens in women with newly diagnosed, advanced-stage EOC.
|
Authors | Gisele A Sarosy, Mahrukh M Hussain, Michael V Seiden, Arlan F Fuller, Najmosama Nikrui, Annekathryn Goodman, Lori Minasian, Eddie Reed, Seth M Steinberg, Elise C Kohn |
Journal | Cancer
(Cancer)
Vol. 116
Issue 6
Pg. 1476-84
(Mar 15 2010)
ISSN: 0008-543X [Print] United States |
PMID | 20091841
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Intramural)
|
Chemical References |
- Cyclophosphamide
- Paclitaxel
- Cisplatin
|
Topics |
- Adenocarcinoma
(drug therapy, mortality, pathology)
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Cisplatin
(administration & dosage)
- Cyclophosphamide
(administration & dosage)
- Drug Administration Schedule
- Female
- Humans
- Middle Aged
- Ovarian Neoplasms
(drug therapy, pathology)
- Paclitaxel
(administration & dosage)
- Prognosis
- Treatment Outcome
|